FRX Forest Laboratories Inc.
- 86.13 P/E
- 3.55 P/S
- 1.91 P/B
- -0.12 EPS
- 43.39% Cash ROIC
- 2.61 Cash Ratio
- 0 / 0% Dividend
- 1.41M Avg. Vol.
- 266.67M Shares
- 11.075B Market Cap.
Forest Laboratories, Inc. develops, manufactures, and sells branded and generic forms of ethical drug products. Its principal products include Lexapro for the treatment of depression in adults and adolescents, and generalized anxiety disorder in adults; Namenda for the treatment of Alzheimer's disease; Bystolic for the treatment of hypertension; and Savella for the management of fibromyalgia. The ...
Seeking Alpha - Jun 11, 2013
4-traders (press release) - Jun 11, 2013
Forest Labs to add Icahn rep to board, avert proxy fight - Reuters
Insider Monkey (blog) - May 28, 2013
4-traders (press release) - Jun 13, 2013
Forbes - Jun 11, 2013
4-traders (press release) - May 23, 2013
Forest Laboratories CEO Solomon to Retire Dec. 31 - Wall Street Journal
ValueWalk - Jun 7, 2013
Exclusive: Forest braces for third bout with Icahn - Reuters
4-traders (press release) - May 24, 2013
Forbes - May 23, 2013
Watch List News (press release) - Jun 14, 2013